[
bharat biotech
]PAGE 2
Covid-19 vaccine: Data India seeks from Serum Institute, Bharat Biotech; Canada’s approval to Pfizer vaccine shot | 10 points
By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON DEC 10, 2020 08:33 AM IST
Bharat Biotech will have to submit the safety and efficacy data from the ongoing phase 3 clinical trial in the country.
Covid-19: Expert panel seeks more data from Serum Institute of India, Bharat Biotech
By Agencies | New Delhi
UPDATED ON DEC 09, 2020 10:15 PM IST
The expert committee of the Central Drugs Standard Control Organisation (CDSCO) on Wednesday sought additional safety and efficacy data from the Serum Institute of India and Bharat Biotech for their coronavirus disease (Covid-19) vaccine, after deliberating upon their applications seeking authorisation for the shots.
India playing key role against Covid-19, says Bharat Biotech as 64 envoys visit facility
By Srinivasa Rao Apparasu | Hindustan Times, Hyderabad
UPDATED ON DEC 09, 2020 07:01 PM IST
Bharat Biotech said the envoys appreciated its work of national and global public health significance, through several months to establish a long-lasting efficacious vaccine to combat the extraordinary Covid-19 pandemic
Covid-19 vaccine drive: Centre to send additional storage equipment to states from tomorrow
By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON DEC 09, 2020 06:02 PM IST
The present cold chain system consists of 85,634 equipment for storage of vaccine at about 28,947 cold chain points across the country.
Covid-19 vaccine: Applications of Pfizer, Bharat Biotech and Serum Institute to be reviewed today
By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON DEC 09, 2020 09:57 AM IST
The experts will go through the voluminous trial data of the vaccine candidates and once they are satisfied with the risk-benefit ratio, they will give the go-ahead.
Foreign ministry to fly over 60 foreign envoys to Hyderabad for Covid vaccine briefing
By Shishir Gupta | Hindustan Times, New Delhi
UPDATED ON DEC 08, 2020 07:28 PM IST
The diplomats will be taken to the Hyderabad-based Bharat Biotech and Biological E for an interaction with scientists on the Covid-19 vaccine
Pfizer, Serum Institute and Bharat Biotech apply for EUA in India: Here’s what might happen next
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON DEC 08, 2020 02:27 PM IST
America’s Pfizer was the first firm to apply for EUA in India. Serum Institute and Bharat Biotech, both Indian firms, followed next.
Covid-19 vaccine update: UK to begin Pfizer vaccinations, Bharat Biotech seeks nod for emergency use in India
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON DEC 08, 2020 08:07 AM IST
South Korea’s government has said it has signed deals with four firms-AstraZeneca, Pfizer, Moderna and Johnson & Johnson-to vaccinate a total of 44 million people.
Review of Covid vaccine applications of Pfizer, SII, Bharat Biotech tomorrow: Report
By Press Trust of India | Posted by Kanishka Sarkar | New Delhi
UPDATED ON DEC 08, 2020 06:16 AM IST
The decision was taken late on Monday evening after the Hyderabad-based Bharat Biotech became the third pharmaceutical firm to apply to the Drugs Controller General of India (DCGI) for emergency use authorisation for its indigenously developed Covid-19 vaccine Covaxin.
Bharat Biotech seeks emergency use authorization for Covid-19 vaccine
By Press Trust of India | Posted by Nilavro Ghosh | New Delhi
UPDATED ON DEC 07, 2020 10:57 PM IST
The company filed its application with the Drugs Controller General of India earlier on Monday, the source said.
Safety primary criteria in vaccine development: Covaxin maker Bharat Biotech after Anil Vij contracts Covid-19
By hindustantimes.com| Edited by Mallika Soni | Hindustan Times, New Delhi
UPDATED ON DEC 05, 2020 06:47 PM IST
Bharat Biotech recently announced the beginning of Phase 3 trials of Covaxin among 26,000 volunteers across 25 sites in partnership with the Indian Council of Medical Research (ICMR). It is the largest clinical trial conducted for a Covid-19 vaccine in India
Bharat Biotech’s Covaxin: List of states which have started phase 3 trials of Covid-19 vaccine
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON DEC 02, 2020 04:04 PM IST
On November 16, Bharat Biotech had announced the commencement of the third phase trials of Covaxin, which it has developed in collaboration with the Indian Council of Medical Research (ICMR).
PM congratulates scientists at Bharat Biotech for progress in Covaxin trials
By Srinivasa Rao Apparasu | Hindustan Times, Hyderabad
UPDATED ON NOV 28, 2020 06:43 PM IST
The phase 3 trial is being conducted across India on 26,000 participants.
No complaint from volunteers given Bharat Biotech’s Covaxin: Ahmedabad doctor
By hindustantimes.com | Edited by Meenakshi Ray | Hindustan Times, New Delhi
UPDATED ON NOV 27, 2020 05:41 PM IST
Dr Parul Bhatt, the medical superintendent of the Sola Civil Hospital in Gujarat’s Ahmedabad, said the second dose of Bharat Biotech International Limited’s Covid-19 vaccine will now be given after 28 days.
Covid-19 vaccine update: PM Modi to visit vaccine development centres, AstraZeneca eyes second global trial
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 27, 2020 07:44 AM IST
Russia has suggested its vaccine candidate, Sputnik V, can be combined with AstraZeneca’s candidate to boost latter’s efficacy. Canada, meanwhile, could approve Pfizer Inc’s vaccine candidate in December.
Covid-19 vaccine update: COVAXIN trials in Gujarat, AstraZeneca admits ‘error’
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 26, 2020 05:06 PM IST
China National Biotec Group Company has applied to Chinese health regulators to bring its candidate to the market. In Brazil, meanwhile, America’s Pfizer Inc has started the process to get its candidate registered.
Covid-19 vaccine update: India to immunise 250 million citizens, US vaccinations might begin in December
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 23, 2020 01:42 PM IST
The United Kingdom could give approval to Pfizer’s vaccine candidate this week, a report claimed. Meanwhile, the official Twitter account of Russia’s vaccine candidate Sputnik V claimed the price per dose of the vaccine would be “much lower” than that of Moderna and Pfizer’s vaccine candidates.
Covid-19 vaccine updates: Bharat Biotech to recruit volunteers for trial, Pfizer files for emergency use authorisation
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 21, 2020 08:13 AM IST
Britain’s AstraZeneca has launched phase three trials of an antibody combination drug, called AZD7442, that it hopes could be used to protect those at risk of contracting the coronavirus disease for up to 12 months.
Haryana health minister Anil Vij takes trial shot of Bharat Biotech’s Covid-19 vaccine
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 20, 2020 06:48 PM IST
Vij, who also holds the state home portfolio, had volunteered to be the first candidate for the trial shot of Covaxin. Bharat Biotech has started conducting phase 3 trials of the vaccine candidate.
Covid-19 vaccine update: Covaxin phase 3 trials to begin in Haryana today, minister to take shot
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 20, 2020 08:27 AM IST
Adar Poonawalla, the chief executive of Serum Institute of India, said his company may sell Covishield, the Covid-19 vaccine being developed by Oxford University, for around Rs 500-600 per shot.
Bharat Biotech vaccine trial results out soon
By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON NOV 20, 2020 08:08 AM IST
The company recently announced that it had started phase 3 trials for its vaccine candidate which is India’s first vaccine candidate against Covid-19.
Two out of five Covid-19 vaccines in Phase 3 trial stage: Govt
By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON NOV 18, 2020 06:32 AM IST
The two include the widely watched Oxford-AstraZeneca vaccine being tested by Serum Institute of India and the domestically developed candidate by Bharat Biotech.
Covid-19 vaccine update: Bharat Biotech begins phase 3 trials, Moderna says its candidate nearly 95% effective
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 17, 2020 08:57 AM IST
Meanwhile, Johnson and Johnson has launched a second phase 3 trial, besides its existing one. Also, India is reportedly in talks with several firms over their respective coronavirus vaccine candidates with regards to the progress of trials, vaccine efficacy, safety etc.
Covid-19: Bharat Biotech begins Phase 3 trials of Covaxin in India
By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON NOV 17, 2020 06:10 AM IST
The trial will be conducted in partnership with the Indian Council of Medical Research (ICMR), the Hyderabad-based drugmaker said in a statement.
Covid-19 vaccine update: Bharat Biotech candidate launch and AstraZeneca’s hopes
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 06, 2020 06:43 PM IST
Hungary has said it will import small doses of Russian-made Sputnik V for late stage trials, by December. Meanwhile, Australia has agreed to buy 50 million more doses of two more vaccine candidates.
Covid-19 vaccine update: Bharat Biotech to launch candidate in Q2 2021, Israel starts human trials
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON NOV 02, 2020 08:17 AM IST
AstraZeneca, meanwhile, has said Britain’s health regulator has started an ‘accelerated’ review. Its vaccine candidate is called ‘AZD1222’ and is being developed in partnership with the University of Oxford.
Bharat Biotech to launch Covaxin in Q2 2021
By Press Trust of India| Posted by Susmita Pakrasi | Hindustan Times, New Delhi
PUBLISHED ON NOV 01, 2020 11:27 AM IST
The company’s vaccine candidate -Covaxin- has been developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV) using inactivated Sars-Cov-2, the virus that causes Covid-19. The virus was isolated in an ICMR lab.
Bharat Biotech to submit revised Phase 3 clinical trial protocol to DCGI by next week
By Rhythma Kaul | Hindustan Times,New Delhi
UPDATED ON OCT 24, 2020 08:31 AM IST
Covaxin is India’s first vaccine candidate against Covid-19
Bharat Biotech’s Covid-19 vaccine gets nod for Phase 3 trial. Here’s how it came through
By hindustantimes.com | Edited by Meenakshi Ray | Hindustan Times, New Delhi
UPDATED ON OCT 23, 2020 10:02 PM IST
A subject expert committee on Covid-19 had recommended granting permission to Bharat Biotech for conducting latest phase of the clinical trial of its vaccine ‘Covaxin’ after assessing the safety and immunogenicity data of Phase 1 and Phase 2 trials.
Covid-19: Bharat Biotech in talks to take vaccine candidate global
By Reuters| Posted by: Harshit Sabarwal | Bengaluru
UPDATED ON OCT 23, 2020 08:41 PM IST
The company, based in Hyderabad, this week received initial approval from Indian authorities to conduct late-stage trials for its vaccine candidate, COVAXIN.